Allen Institute for Artificial Intelligence logo

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: a year ago

Possible Interaction: Cannabidiol and Gamma-Aminobutyric Acid

Research Papers that Mention the Interaction

Preclinical evidence suggests that one aspect of the polypharmacy of CBD is that it modulates brain excitatory glutamate and inhibitory γ-aminobutyric acid (GABA) levels, including in brain regions linked to ASD, such as the basal ganglia (BG) and the dorsomedial prefrontal cortex (DMPFC).
Neuropsychopharmacology  •  2019  |  View Paper
CBD also increased glutamate decarboxylase 67, the rate-limiting enzyme that converts glutamate to GABA , and parvalbumin protein levels in the HPC.
Brain, Behavior, and Immunity  •  2019  |  View Paper
CBD prevented tonic convulsions caused by a convulsant current (CC) 99.99, and by the convulsant dose (CD) 99.99 values of gamma-aminobutyric acid (GABA) inhibitors, 3-mercaptoproprionic acid (3MPA), picrotoxin (PIC), isonicotinic acid hydrazine (INH), pentylenetetrazol (PTZ) and bicuculline (BIC).
European journal of pharmacology  •  1982  |  View Paper
CBG and CBD are able to influence the expression of the genes involved in glutamate, GABA and dopamine signaling.
On the contrary, CBD is already known to modulate brain excitatory glutamate, inhibitory γ-aminobutyric acid (GABA) and dopamine neurotransmission.
Life  •  2020  |  View Paper
For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia.
Front. Pharmacol.  •  2017  |  View Paper